Verona Pharma Plc (LON: VRP) has reported positive top-line data in 4-week phase 2b COPD study.
- The company has reported positive outcome from the study assessing nebulized ensifentrine (0.375 mg, 0.75 mg, 1.5 mg and 3.0 mg) or placebo as an add-on treatment to tiotropium (Spiriva® Respimat®).
- Study of Ensifentrine as an add-on to tiotropium met all its deadlines and statistically meaningful and clinically significant progress in lung function at week 4 was found.
- For the 3.0 mg dose improvements ranging from 78 mL for the 0.375 mg dose to 124 mL were noticed.
- On 13th January 2020, at the time of writing, GMT 08:22 AM, VRP shares were trading at GBX 91.00, up by 33.00 points or 56.90% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.